Document is current
Any future updates will be listed below
-
Authors
Chaung, Wayne W. http://orcid.org/0000-0002-1646-3814
Brenner, Max
Yen, Hao-Ting
Ochani, Mahendar L.
Jacob, Asha
Wang, Ping
-
Funding
Funding for this research was provided by:
National Institute on Alcohol Abuse and Alcoholism (HHSN275201300007C)
National Institute on Alcohol Abuse and Alcoholism (HHSN275201200002C)
- License Information
-
More Information
Article History
Received: 1 October 2019
Accepted: 4 November 2019
First Online: 20 November 2019
Ethics approval
: All experiments involving live animals were carried out in accordance with the National Institutes of Health guidelines for the use of experimental animals and were reviewed and approved by the Institutional Animal Care and Use Committee at the Feinstein Institute for Medical Research.
: P.W. is an inventor of patents #WO/2006/122327: “Milk fat globule epidermal growth factor-factor VIII and sepsis”, #WO/2009/064448: “Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using MFG-E8”, and WO/2012/149254: “MFG-E8 and uses thereof”. These patent applications cover the fundamental concept of using MFG-E8 for the treatment of inflammatory diseases. TheraSource LLC holds the exclusive option to license the technology from the Feinstein Institutes for Medical Research. P.W. is a co-founder of TheraSource LLC. W.W.C., M.B., T.Y., and M.L.O. are part-time employees of TheraSource LLC.
